Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of OLOMAX in Hypertension with Low-Intermediate CV Risk
NCT04120753Phase 4Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Aug 2019
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of OLOMAX in hypertension (HTN), dyslipidemia, sponsored by Daewoong Pharmaceutical. Started Aug 2019; status: completed.
02
Drugs
OLOMAX
03
Conditions
hypertension (HTN)dyslipidemia
Beyond the preview
Go deeper on NCT04120753.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04120753.